Celldex Therapeutics Inc. is eyeing an accelerated approval pathway after preliminary Phase IIb data showed impressive response rates in three subsets of heavily pretreated breast cancer patients given glycoprotein NMB (GPNMB)-targeting antibody-drug conjugate CDX-011 (glembatumumab vedotin).